Related Experiment Video
Updated: Jul 4, 2026

BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain
Published on: May 26, 2023
Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats
F Matrisciano1, A Caruso, R Orlando
1Department of Physiology and Pharmacology, University of Rome "Sapienza", Piazzale Aldo Moro, 5, 00185 Rome, Italy. fmatrisciano@hotmail.com
Abstract:
Spontaneously depressed flinders sensitive line (FSL) rats showed a reduced expression of mGlu2/3 metabotropic glutamate receptors in the hippocampus, as compared to "non-depressed" flinders resistant line (FRL) rats. No changes in mGlu2/3 receptor protein levels were found in other brain regions, including the amygdala, hypothalamus, and cerebral cortex. Biochemical analysis of receptor signalling supported the reduction of mGlu2/3 receptors in the hippocampus of FSL rats. Accordingly, the selective mGlu2/3 receptor agonist, LY379268 (1microM) reduced forskolin-stimulated cAMP formation by 56% and 32% in hippocampal slices from FRL and FSL rats, respectively. In addition, LY379268 enhanced 3,5-dihydroxyphenylglycine-stimulated inositol phospholipid hydrolysis from 65% to 215% in hippocampal slices from FRL rats, whereas it was inactive in slices from FRL rats. We also examined the behavioural response of FSL rats to systemic injection of LY379268 (0.5mg/kg, i.p., once a day for 1-21 days) by measuring the immobility time in the forced swim test, which is known to be increased in these rats. LY379268 was administered alone or combined with the classical antidepressant, chlorimipramine (10mg/kg, i.p.). LY379268 alone had no effect at any of the selected time-points, whereas chlorimipramine alone reduced the immobility time only after 21 days of treatment. In contrast, when combined with LY379268, chlorimipramine reduced the immobility time during the first 14 days of treatment. These data support the view that mGlu2/3 receptors might be involved in the pathophysiology of depressive disorders, and that pharmacological activation of these receptors may shorten the latency of antidepressant medication.
Insights
Flinders Sensitive Line rats exhibit reduced hippocampal mGlu2/3 receptors, a potential marker for depression. Activating these receptors with LY379268 may accelerate antidepressant effects.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Spontaneously depressed Flinders Sensitive Line (FSL) rats exhibit distinct neurobiological differences compared to non-depressed Flinders Resistant Line (FRL) rats.
- Metabotropic glutamate receptors, specifically mGlu2/3, play a crucial role in neuronal signaling and are implicated in mood regulation.
Purpose of the Study:
- To investigate the expression and function of mGlu2/3 receptors in the hippocampus of FSL rats.
- To evaluate the therapeutic potential of activating mGlu2/3 receptors in a rat model of depression.
Main Methods:
- Quantitative analysis of mGlu2/3 receptor expression in various brain regions of FSL and FRL rats.
- Biochemical assays to assess mGlu2/3 receptor signaling pathways (cAMP formation and inositol phospholipid hydrolysis).
- Behavioral studies using the forced swim test to evaluate the effects of the mGlu2/3 receptor agonist LY379268, alone and in combination with chlorimipramine, in FSL rats.
Main Results:
- FSL rats showed significantly reduced mGlu2/3 receptor expression in the hippocampus, but not in other brain regions.
- Biochemical analyses confirmed reduced mGlu2/3 receptor signaling in FSL rat hippocampus.
- Systemic administration of LY379268 alone did not alter immobility time in the forced swim test, but it significantly shortened the latency of antidepressant action when combined with chlorimipramine.
Conclusions:
- The findings suggest that reduced hippocampal mGlu2/3 receptor expression is associated with depression-like phenotypes in FSL rats.
- Pharmacological activation of mGlu2/3 receptors may represent a viable strategy to enhance the efficacy and expedite the onset of antidepressant treatments.

